WO2002000213A1 - Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition - Google Patents

Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition Download PDF

Info

Publication number
WO2002000213A1
WO2002000213A1 PCT/US2001/020134 US0120134W WO0200213A1 WO 2002000213 A1 WO2002000213 A1 WO 2002000213A1 US 0120134 W US0120134 W US 0120134W WO 0200213 A1 WO0200213 A1 WO 0200213A1
Authority
WO
WIPO (PCT)
Prior art keywords
dosage form
release
pharmaceutical dosage
therapeutic agent
gastric
Prior art date
Application number
PCT/US2001/020134
Other languages
English (en)
French (fr)
Inventor
Moshe Fleshner-Barak
E. Itzhak Lerner
Vered Rosenberger
Mazal Dahan
Yisrael Imakov
Original Assignee
Teva Pharmaceutical Industries Ltd.
Teva Pharmaceuticals Usa, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals Usa, Inc. filed Critical Teva Pharmaceutical Industries Ltd.
Priority to EP01946709A priority Critical patent/EP1305021A4/en
Priority to AU2001268722A priority patent/AU2001268722B8/en
Priority to MXPA02012793A priority patent/MXPA02012793A/es
Priority to AU6872201A priority patent/AU6872201A/xx
Priority to JP2002504995A priority patent/JP2004501190A/ja
Priority to HU0301465A priority patent/HUP0301465A3/hu
Priority to CA002412490A priority patent/CA2412490A1/en
Priority to EA200300046A priority patent/EA200300046A1/ru
Priority to IL15349701A priority patent/IL153497A0/xx
Publication of WO2002000213A1 publication Critical patent/WO2002000213A1/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Manufacturing & Machinery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
PCT/US2001/020134 2000-06-23 2001-06-22 Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition WO2002000213A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP01946709A EP1305021A4 (en) 2000-06-23 2001-06-22 RAPID EXPANSION COMPOSITION FOR GASTRIC RETENTION AND REGULATED RELEASE OF THERAPEUTIC AGENTS, AND DOSAGE FORMS COMPRISING THE SAME
AU2001268722A AU2001268722B8 (en) 2000-06-23 2001-06-22 Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
MXPA02012793A MXPA02012793A (es) 2000-06-23 2001-06-22 Composicion de dilatacion rapida para la retencion gastrica y la liberacion controlada de agentes terapeuticos y formas de dosificacion de la composicion.
AU6872201A AU6872201A (en) 2000-06-23 2001-06-22 Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
JP2002504995A JP2004501190A (ja) 2000-06-23 2001-06-22 治療薬の胃部保留および制御された放出のための急速膨張する組成物とその組成物を含む剤形
HU0301465A HUP0301465A3 (en) 2000-06-23 2001-06-22 Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
CA002412490A CA2412490A1 (en) 2000-06-23 2001-06-22 Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
EA200300046A EA200300046A1 (ru) 2000-06-23 2001-06-22 Быстро увеличивающаяся в объеме композиция для удерживания и контролированного выделения терапевтических агентов в желудке и лекарственные формы, включающие композицию
IL15349701A IL153497A0 (en) 2000-06-23 2001-06-22 Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US21383200P 2000-06-23 2000-06-23
US60/213,832 2000-06-23
US21711000P 2000-07-10 2000-07-10
US60/217,110 2000-07-10
US22321200P 2000-08-04 2000-08-04
US60/223,212 2000-08-04

Publications (1)

Publication Number Publication Date
WO2002000213A1 true WO2002000213A1 (en) 2002-01-03

Family

ID=27395915

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/020134 WO2002000213A1 (en) 2000-06-23 2001-06-22 Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition

Country Status (11)

Country Link
EP (1) EP1305021A4 (es)
JP (1) JP2004501190A (es)
KR (1) KR20030013460A (es)
AU (2) AU2001268722B8 (es)
CA (1) CA2412490A1 (es)
CZ (1) CZ2003199A3 (es)
EA (1) EA200300046A1 (es)
HU (1) HUP0301465A3 (es)
IL (1) IL153497A0 (es)
MX (1) MXPA02012793A (es)
WO (1) WO2002000213A1 (es)

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003015745A1 (en) * 2001-08-16 2003-02-27 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Expandable gastric retention device
WO2004091601A1 (fr) * 2003-04-17 2004-10-28 Jallal Messadek Formulations orales flottantes pour la liberation controlee de la betaine
EP1507518A1 (en) * 2002-05-29 2005-02-23 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
WO2005042101A1 (en) * 2003-10-20 2005-05-12 Teva Pharmaceutical Industries Ltd. Composition and dosage form for sustained effect of levodopa
WO2005101983A2 (en) 2004-03-25 2005-11-03 Sun Pharmaceutical Industries Limited Gastric retention system
WO2006021692A1 (fr) * 2004-08-19 2006-03-02 Sanofi-Aventis Composition pharmaceutique sous forme de comprime a residence gastrique contenant un principe actif
WO2008030830A2 (en) * 2006-09-08 2008-03-13 Drugtech Corporation Sustained-release composition and method of use thereof
WO2008087882A1 (ja) 2007-01-15 2008-07-24 Kissei Pharmaceutical Co., Ltd. 胃内滞留型レボドパ徐放性製剤
WO2008148478A2 (de) * 2007-06-04 2008-12-11 Lts Lohmann Therapie-Systeme Ag Gastroretentives system mit alginat-körper
EP2063865A1 (en) * 2006-05-31 2009-06-03 Solvay Pharmaceuticals GmbH Long term 24 hour intestinal administration of levodopa/carbidopa
EP2066303A2 (en) * 2006-09-26 2009-06-10 Plensat, LLC Method and system for treatment of eating disorders
US7608640B2 (en) 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
WO2010019915A1 (en) * 2008-08-15 2010-02-18 Depomed Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders
US7780990B2 (en) 2005-02-15 2010-08-24 Jallal Messadek Combination therapeutic compositions and method of use
US7786077B2 (en) 2005-04-27 2010-08-31 Jallal Messadek Insulins combinations
US8318805B2 (en) 2004-11-10 2012-11-27 Jallal Messadek Modulation of nitric oxide synthases by betaines
US8343947B2 (en) 2003-07-15 2013-01-01 Jallal Messadek Therapeutic treatment
CN103385871A (zh) * 2012-05-07 2013-11-13 新疆医科大学 复方左旋多巴微囊漂浮片
US8865201B2 (en) 2006-06-29 2014-10-21 Polichem Sa Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant in the manufacture of a medicament for treating female genital disorders
WO2014174388A1 (en) * 2013-03-29 2014-10-30 Wockhardt Limited Modified release pharmaceutical compositions of methylphenidate or salts thereof
WO2014176389A1 (en) * 2013-04-24 2014-10-30 Temple University - Of The Commonwealth System Of Higher Education Solid dosage form containing arabinogalactan
WO2015083171A1 (en) * 2013-12-05 2015-06-11 Tulip Medical Ltd. Retentive devices and systems for in-situ release of pharmaceutical active agents
EP2921170A1 (en) * 2002-05-29 2015-09-23 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US9320738B2 (en) 2008-06-30 2016-04-26 Tocagen Inc. Formulations of 5-fluorocytosine and uses thereof
US10022447B2 (en) 2005-11-02 2018-07-17 Warner-Lambert Company Llc Solid pharmaceutical compositions containing pregabalin
US10098845B2 (en) 2013-10-07 2018-10-16 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
WO2018232413A1 (en) 2017-06-16 2018-12-20 Kashiv Pharma Llc Gastroretentive dosage forms for sustained drug delivery
US10507127B2 (en) 2012-06-07 2019-12-17 Epitomee Medical Ltd. Expandable device
WO2020006278A1 (en) 2018-06-27 2020-01-02 Kashiv Biosciences, Llc Self-regulating osmotic gastroretentive drug delivery systems
US10588863B2 (en) 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
WO2020230089A1 (en) 2019-05-14 2020-11-19 Clexio Biosciences Ltd. Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10987311B2 (en) 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
US11229606B2 (en) 2018-06-18 2022-01-25 Amneal Complex Products Research Llc Extended release compositions comprising pyridostigmine
US20220257543A1 (en) * 2021-02-17 2022-08-18 SpringWorks Therapeutics Inc. Dispersible formulations of n-((r)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
WO2022195476A1 (en) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Gastroretentive devices for assessment of intragastric conditions

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005132803A (ja) * 2003-10-31 2005-05-26 Ono Pharmaceut Co Ltd 胃内滞留固形剤
KR20080076382A (ko) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
CA2694602A1 (en) * 2007-07-27 2009-02-05 Depomed, Inc. Pulsatile gastric retentive dosage forms
CA2742680C (en) * 2008-11-07 2013-12-31 Samyang Corporation Pharmaceutical compositions for release control of methylphenidate
WO2012093974A1 (en) * 2011-01-06 2012-07-12 Mahmut Bilgic Improved bisphosphonate formulations
JP6204141B2 (ja) * 2013-04-22 2017-09-27 テイカ製薬株式会社 口腔内速崩壊性固形製剤用組成物
AU2016225052B2 (en) * 2015-02-27 2021-07-08 Cingulate Therapeutics LLC Tripulse release stimulant formulations
JP6823539B2 (ja) * 2017-05-26 2021-02-03 株式会社ファンケル 胃内滞留性錠剤
JP7044649B2 (ja) * 2018-06-28 2022-03-30 株式会社ファンケル 胃内浮遊錠剤
WO2021176360A1 (en) * 2020-03-02 2021-09-10 Craft Health Pte Ltd Oral dosage forms for extended drug release

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4167558A (en) * 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
US4434153A (en) * 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
AU8578498A (en) * 1997-07-23 1999-02-16 Perio Products Ltd. Tannic acid-polymer compositions for controlled release of pharmaceutical agents, particularly in the oral cavity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4167558A (en) * 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
US4434153A (en) * 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1305021A4 *

Cited By (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608640B2 (en) 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
WO2003015745A1 (en) * 2001-08-16 2003-02-27 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Expandable gastric retention device
EP1507518A1 (en) * 2002-05-29 2005-02-23 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
EP1507518A4 (en) * 2002-05-29 2010-01-13 Impax Laboratories Inc ASSOCIATION OF POSOLOGICAL FORMS OF LEVODOPA / CARBIDOPA WITH IMMEDIATE AND CONTROLLED RELEASE
EP2921170A1 (en) * 2002-05-29 2015-09-23 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
WO2004091601A1 (fr) * 2003-04-17 2004-10-28 Jallal Messadek Formulations orales flottantes pour la liberation controlee de la betaine
US8343947B2 (en) 2003-07-15 2013-01-01 Jallal Messadek Therapeutic treatment
AU2004285436B2 (en) * 2003-10-20 2009-01-08 Teva Pharmaceutical Industries Ltd. Composition and dosage form for sustained effect of levodopa
WO2005042101A1 (en) * 2003-10-20 2005-05-12 Teva Pharmaceutical Industries Ltd. Composition and dosage form for sustained effect of levodopa
AU2004285436C1 (en) * 2003-10-20 2009-07-16 Teva Pharmaceutical Industries Ltd. Composition and dosage form for sustained effect of levodopa
JP2007509146A (ja) * 2003-10-20 2007-04-12 テバ ファーマシューティカル インダストリーズ リミティド レボドーパの持続効果のための組成物及び投与形
US9439851B2 (en) 2004-03-25 2016-09-13 Sun Pharma Advanced Research Company Ltd. Gastric retention system
WO2005101983A2 (en) 2004-03-25 2005-11-03 Sun Pharmaceutical Industries Limited Gastric retention system
AU2005235239B2 (en) * 2004-03-25 2011-06-23 Sun Pharma Advanced Research Company Limited Gastric retention system
WO2005101983A3 (en) * 2004-03-25 2006-04-27 Sun Pharmaceutical Ind Ltd Gastric retention system
EA011151B1 (ru) * 2004-03-25 2009-02-27 Сан Фармацевтикал Индастрис Лимитед Система, задерживающаяся в желудке
JP2007530530A (ja) * 2004-03-25 2007-11-01 サン・ファーマシューティカル・インダストリーズ・リミテッド 胃貯留系
WO2006021692A1 (fr) * 2004-08-19 2006-03-02 Sanofi-Aventis Composition pharmaceutique sous forme de comprime a residence gastrique contenant un principe actif
AU2005276307B2 (en) * 2004-08-19 2011-02-24 Sanofi-Aventis Pharmaceutical composition in the form of a gastric-resident tablet containing an active principle
EA012981B1 (ru) * 2004-08-19 2010-02-26 Санофи-Авентис Фармацевтическая композиция в форме таблетки для нахождения в желудке, содержащая активное вещество
CN101022808B (zh) * 2004-08-19 2013-05-29 赛诺菲-安万特 含有活性组分的胃滞留片剂的药物组合物
US8318805B2 (en) 2004-11-10 2012-11-27 Jallal Messadek Modulation of nitric oxide synthases by betaines
US7780990B2 (en) 2005-02-15 2010-08-24 Jallal Messadek Combination therapeutic compositions and method of use
US7786077B2 (en) 2005-04-27 2010-08-31 Jallal Messadek Insulins combinations
US10022447B2 (en) 2005-11-02 2018-07-17 Warner-Lambert Company Llc Solid pharmaceutical compositions containing pregabalin
EP2063865A1 (en) * 2006-05-31 2009-06-03 Solvay Pharmaceuticals GmbH Long term 24 hour intestinal administration of levodopa/carbidopa
US8865201B2 (en) 2006-06-29 2014-10-21 Polichem Sa Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant in the manufacture of a medicament for treating female genital disorders
WO2008030830A2 (en) * 2006-09-08 2008-03-13 Drugtech Corporation Sustained-release composition and method of use thereof
WO2008030830A3 (en) * 2006-09-08 2008-05-29 Drugtech Corp Sustained-release composition and method of use thereof
EP2066303A4 (en) * 2006-09-26 2010-07-28 Plensat Llc METHOD AND SYSTEM FOR THE TREATMENT OF FOODSTUFFS
EP2066303A2 (en) * 2006-09-26 2009-06-10 Plensat, LLC Method and system for treatment of eating disorders
WO2008087882A1 (ja) 2007-01-15 2008-07-24 Kissei Pharmaceutical Co., Ltd. 胃内滞留型レボドパ徐放性製剤
EP2497465A2 (de) 2007-06-04 2012-09-12 LTS LOHMANN Therapie-Systeme AG Gastroretentives System mit Alginat-Körper
EP2497465A3 (de) * 2007-06-04 2012-11-21 LTS LOHMANN Therapie-Systeme AG Gastroretentives System mit Alginat-Körper
RU2468790C2 (ru) * 2007-06-04 2012-12-10 Лтс Ломанн Терапи-Зюстеме Аг Способная задерживаться в желудке система, содержащая вещество на основе альгината
WO2008148478A3 (de) * 2007-06-04 2009-04-09 Lohmann Therapie Syst Lts Gastroretentives system mit alginat-körper
DE102007026037A1 (de) 2007-06-04 2008-12-11 Lts Lohmann Therapie-Systeme Ag Gastroretentives System mit Alginat-Körper
WO2008148478A2 (de) * 2007-06-04 2008-12-11 Lts Lohmann Therapie-Systeme Ag Gastroretentives system mit alginat-körper
AU2008258881B2 (en) * 2007-06-04 2013-12-19 Lts Lohmann Therapie-Systeme Ag Gastroretentive system comprising an alginate body
US9320738B2 (en) 2008-06-30 2016-04-26 Tocagen Inc. Formulations of 5-fluorocytosine and uses thereof
US10449194B2 (en) 2008-06-30 2019-10-22 Tocagen Inc. Formulations of 5-fluorocytosine and uses thereof
US11191764B2 (en) 2008-06-30 2021-12-07 Denovo Biopharma Llc Formulations of 5-fluorocytosine and uses thereof
US9889133B2 (en) 2008-06-30 2018-02-13 Tocagen Inc. Formulations of 5-fluorocytosine and uses thereof
AU2009281752B2 (en) * 2008-08-15 2016-11-17 Depomed Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of CNS disorders
US9566258B2 (en) 2008-08-15 2017-02-14 Depomed, Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of CNS disorders
US9161911B2 (en) 2008-08-15 2015-10-20 Depomed, Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of CNS disorders
US9937142B2 (en) 2008-08-15 2018-04-10 Depomed, Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of CNS disorders
WO2010019915A1 (en) * 2008-08-15 2010-02-18 Depomed Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders
CN103385871A (zh) * 2012-05-07 2013-11-13 新疆医科大学 复方左旋多巴微囊漂浮片
CN103385871B (zh) * 2012-05-07 2017-06-23 新疆医科大学 复方左旋多巴微囊漂浮片
US11712356B2 (en) 2012-06-07 2023-08-01 Epitomee Medical Ltd Expanded device
US10507127B2 (en) 2012-06-07 2019-12-17 Epitomee Medical Ltd. Expandable device
WO2014174388A1 (en) * 2013-03-29 2014-10-30 Wockhardt Limited Modified release pharmaceutical compositions of methylphenidate or salts thereof
WO2014176389A1 (en) * 2013-04-24 2014-10-30 Temple University - Of The Commonwealth System Of Higher Education Solid dosage form containing arabinogalactan
US10994013B2 (en) 2013-04-24 2021-05-04 Temple University—Of the Commonwealth System of Higher Education Solid dosage form containing arabinogalactan
US11357733B2 (en) 2013-10-07 2022-06-14 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10292935B2 (en) 2013-10-07 2019-05-21 Impax Laboratories, Inc. Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US11666538B2 (en) 2013-10-07 2023-06-06 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10688058B2 (en) 2013-10-07 2020-06-23 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US11622941B2 (en) 2013-10-07 2023-04-11 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10973769B2 (en) 2013-10-07 2021-04-13 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10098845B2 (en) 2013-10-07 2018-10-16 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US11129793B2 (en) 2013-12-05 2021-09-28 Epitomee Medical Ltd Retentive devices and systems for in-situ release of pharmaceutical active agents
CN105899198A (zh) * 2013-12-05 2016-08-24 图利普医疗有限公司 用于药物活性试剂的原位释放的滞留装置和系统
CN114668960A (zh) * 2013-12-05 2022-06-28 意比图密医疗有限公司 用于药物活性试剂的原位释放的滞留装置和系统
AU2014358675B2 (en) * 2013-12-05 2019-10-03 Epitomee Medical Ltd Retentive devices and systems for in-situ release of pharmaceutical active agents
WO2015083171A1 (en) * 2013-12-05 2015-06-11 Tulip Medical Ltd. Retentive devices and systems for in-situ release of pharmaceutical active agents
US10857098B2 (en) 2017-06-16 2020-12-08 Kashiv Specialty Pharmaceuticals, Llc Gastroretentive dosage forms for sustained drug delivery
US10744093B2 (en) 2017-06-16 2020-08-18 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
US10987311B2 (en) 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
US10918597B2 (en) 2017-06-16 2021-02-16 Kashiv Specialty Pharmaceuticals, Llc Gastroretentive dosage forms for sustained drug delivery
US10588863B2 (en) 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
WO2018232413A1 (en) 2017-06-16 2018-12-20 Kashiv Pharma Llc Gastroretentive dosage forms for sustained drug delivery
US11478425B2 (en) 2017-06-16 2022-10-25 Amneal Complex Products Research Llc Extended release compositions comprising pyridostigmine
US11229606B2 (en) 2018-06-18 2022-01-25 Amneal Complex Products Research Llc Extended release compositions comprising pyridostigmine
EP3970701A1 (en) 2018-06-27 2022-03-23 Amneal Complex Products Research LLC Self-regulating osmotic gastroretentive drug delivery systems
US11793747B2 (en) 2018-06-27 2023-10-24 Amneal Complex Products Research Llc Self-regulating osmotic gastroretentive drug delivery systems
WO2020006278A1 (en) 2018-06-27 2020-01-02 Kashiv Biosciences, Llc Self-regulating osmotic gastroretentive drug delivery systems
US11666536B2 (en) 2018-08-30 2023-06-06 Amneal Complex Products Research Llc Extended release compositions comprising pyridostigmine
US11389398B2 (en) * 2019-05-14 2022-07-19 Clexio Biosciences Ltd. Gastroretentive treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
WO2020230089A1 (en) 2019-05-14 2020-11-19 Clexio Biosciences Ltd. Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
US11571402B2 (en) * 2021-02-17 2023-02-07 Springworks Therapeutics, Inc. Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US20220257543A1 (en) * 2021-02-17 2022-08-18 SpringWorks Therapeutics Inc. Dispersible formulations of n-((r)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
WO2022195476A1 (en) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Gastroretentive devices for assessment of intragastric conditions

Also Published As

Publication number Publication date
EP1305021A1 (en) 2003-05-02
EP1305021A4 (en) 2009-09-23
KR20030013460A (ko) 2003-02-14
HUP0301465A3 (en) 2006-07-28
MXPA02012793A (es) 2004-07-30
HUP0301465A2 (hu) 2004-05-28
AU6872201A (en) 2002-01-08
EA200300046A1 (ru) 2003-10-30
CA2412490A1 (en) 2002-01-03
AU2001268722B8 (en) 2005-09-29
AU2001268722B2 (en) 2005-08-11
IL153497A0 (en) 2003-07-06
CZ2003199A3 (cs) 2003-12-17
JP2004501190A (ja) 2004-01-15

Similar Documents

Publication Publication Date Title
AU2001268722B2 (en) Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US7674480B2 (en) Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
AU2001268722A1 (en) Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6881420B2 (en) Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
US6476006B2 (en) Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
AU736052B2 (en) Pharmaceutical compositions for controlled release of active substances
RU2385712C2 (ru) Рецептура с контролируемым высвобождением
EP0795324B1 (en) A pharmaceutical tablet characterized by showing a high volume increase when coming into contact with biological fluids
Kotreka et al. Gastroretentive floating drug-delivery systems: a critical review
RU2325163C2 (ru) Композиции с пролонгированным высвобождением, включающие ламотригин
US20040052844A1 (en) Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins
EP1916995B1 (en) Ph-controlled pulsatile delivery system, methods for preparation and use thereof
AU2001268719A1 (en) Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US20060153918A1 (en) Dosage forms with an enterically coated core tablet
WO2007106957A1 (en) Multiple units controlled-release floating dosage forms
CA2606740A1 (en) Quinine-containing controlled-release formulations
WO1998027967A1 (en) Release-controlled coated tablets
US20180015080A1 (en) Compositions and methods for treatment in parkinson's disease patients
CZ298851B6 (cs) Tableta pro rízené podávání úcinných látek
Reshma Formulation and Evaluation of Olmesartan Medoxomil Pulsatile Drug Delivery System

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 153497

Country of ref document: IL

Ref document number: 2001268722

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/012793

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2412490

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020027017538

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2002 504995

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001946709

Country of ref document: EP

Ref document number: PV2003-199

Country of ref document: CZ

Ref document number: 200300046

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1020027017538

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001946709

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2003-199

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 2001268722

Country of ref document: AU